

# Biomarkers and rapid imaging in dementia diagnosis

<b>Submission date</b>	<b>Recruitment status</b>	<input type="checkbox"/> Prospectively registered
30/10/2023	Recruiting	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
21/02/2024	Ongoing	<input type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
21/01/2026	Mental and Behavioural Disorders	<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

MRI is an essential part of the diagnostic workup in dementia, however, the time taken and cost limit its availability. Reduction in scan time will solve these issues. This study aims to develop an ultra-fast MRI scan cutting the gold-standard MRI scan from 30 to 7 minutes, with these scans providing non-inferior images to aid in dementia diagnosis.

### Who can participate?

Patients referred to the National Hospital for Neurology and Neurosurgery

### What does the study involve?

The study involves a standard clinical MRI scan (30 minutes) with an additional 7 minutes for the ultra-fast scan, donation of a blood sample and 10 minutes of neuropsychology

### What are the possible benefits and risks of participating?

There is no direct benefit for participating in the study. Some people experience minor discomfort, bruising or swelling following a blood draw. There is also a small risk of developing an infection at the site of blood draw. MRI scans may feel slightly uncomfortable due to the noise the machine makes. The table you lie on may feel hard, and the room may be cool, but the medical team will do everything they can to make you comfortable and blankets may be provided. You may be tired or sore from lying in one position for a long time. Some people experience claustrophobia when having a scan, but the medical team will do whatever they can to help you relax before and during the scan. The MRI scanner produces loud tapping, knocking, chirping and squeaking sounds during the scans. Before your scan, the technicians will give you disposable foam ear plugs and headphones to wear to protect your hearing from the loud noise. Cognitive testing can be mentally tiring but is unlikely to cause any harm.

### Where is the study run from?

National Hospital for Neurology and Neurosurgery (UK)

### When is the study starting and how long is it expected to run for?

August 2021 to June 2026

Who is funding the study?

1. Biogen
2. Alzheimer's Society
3. Rosetrees Trust

Who is the main study contact?

1. Millie Beament, [m.beament@ucl.ac.uk](mailto:m.beament@ucl.ac.uk)
2. Prof. Nick Fox, [n.fox@ucl.ac.uk](mailto:n.fox@ucl.ac.uk)

## Contact information

**Type(s)**

Scientific, Principal investigator

**Contact name**

Prof Nicholas Fox

**Contact details**

First Floor 8-11 Queen Square  
London  
United Kingdom  
WC1N 3AR  
+44 (0)20 3448 4773  
[n.fox@ucl.ac.uk](mailto:n.fox@ucl.ac.uk)

**Type(s)**

Public

**Contact name**

Miss Millie Beament

**Contact details**

First Floor 8-11 Queen Square  
London  
United Kingdom  
WC1N 3AR  
+44 (0)20 3448 4773  
[m.beament@ucl.ac.uk](mailto:m.beament@ucl.ac.uk)

## Additional identifiers

**Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

291170

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

CPMS 51048, IRAS 291170

## Study information

**Scientific Title**

Biomarkers & accelerate magnetic resonance imaging for dementia diagnosis

**Acronym**

B-RAPIDD

**Study objectives**

There is overwhelming pressure on healthcare systems to provide wider and more timely access to a dementia diagnosis. Structural MRI scans are an essential part of the diagnostic workup in dementia but their availability is confounded by their price and time taken. Making a substantial reduction in scan time would tackle these issues and mean that MRI would be available to most cases. This study develops an ultra-fast scanning protocol shortening scan time from 30 minutes to 7 minutes without impacting image quality. We will assess the ability of ultra-fast MRI to aid in dementia diagnosis and measure change over time, over short and longer intervals.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 11/01/2022, London - Hampstead Research Ethics Committee (Ground Floor, Temple Quay House, 2 The Square, Bristol, BS1 6PN, United Kingdom; +44 (0)207 104 8248, +44 (0)207 104 8284, +44 (0)207 104 8227; hampstead.rec@hra.nhs.uk), ref: 21/LO/0815

**Study design**

Single-centre cross-sectional observational cohort study

**Primary study design**

Observational

**Study type(s)**

Diagnostic

**Health condition(s) or problem(s) studied**

Dementia

**Interventions**

170 participants from the cognitive disorders clinic at the National Hospital for Neurology and Neurosurgery (UCLH) will be recruited. These participants are due to have a same-day MRI scan which takes 30 minutes, this study adds an additional 7 minutes in scanning time. They will also be asked to provide a blood sample and undergo a brief neuropsychological examination.

Participants in the longitudinal sub-studies will have the same as above at their first visit, with repeat scanning at subsequent visits, as well as optional blood sample collections.

**Intervention Type**

Other

### **Primary outcome(s)**

Non-inferiority of ultra-fast MRI compared to gold standard MRI assessed using a 5-point Likert scale at baseline

### **Key secondary outcome(s)**

1. Stability of ultra-fast MRI compared to gold standard MRI, assessed using a 5-point Likert scale at 2 weeks to 2 months
2. Ability of ultra-fast MRI to track longitudinal change compared to gold standard MRI, assessed using a 5-point Likert scale at 1 year
3. Blood biomarkers assessed by immunoassays at baseline, 2 weeks to 2-month interval and 1-year interval

### **Completion date**

30/06/2026

## **Eligibility**

### **Key inclusion criteria**

1. An individual with ability to engage in the decision to participate in the research study and provide informed consent
2. Aged 18 years old and above

Main study: Patients attending the CDC at NHNN and at Darent Valley Hospital who are due to have a standard-of-care MRI of the brain as part of their routine investigation.

Sub-study 1: Participants in other REC approved studies, who are scheduled for a planned MRI brain scan

Sub-study 2: Healthy controls recruited through spouses/partners of patients, individuals who are included on the DRC Research Register and Join Dementia Research and patients attending the CDC at NHNN and at Darent Valley Hospital

Sub-study 3: Participants recruited to the main study who are happy to be contacted about follow-up study procedures

### **Participant type(s)**

Healthy volunteer, Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

18 years

### **Upper age limit**

100 years

### **Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Unable to tolerate a routine MRI scan plus a 7-minute fast-MRI scan
2. Unable to tolerate draw blood by venepuncture

**Date of first enrolment**

21/03/2022

**Date of final enrolment**

30/06/2026

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**National Hospital for Neurology & Neurosurgery**

Queen Square

London

England

WC1N 3BG

## Sponsor information

**Organisation**

University of London

**ROR**

<https://ror.org/04cw6st05>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Biogen

**Alternative Name(s)**

Biogen Inc.

**Funding Body Type**

Government organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

United States of America

**Funder Name**

Alzheimer's Society

**Alternative Name(s)**

alzheimerssoc

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Associations and societies (private and public)

**Location**

United Kingdom

**Funder Name**

Rosetrees Trust

**Alternative Name(s)**

Teresa Rosenbaum Golden Charitable Trust, Rosetrees

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Trusts, charities, foundations (both public and private)

**Location**

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes